01 December 2020
Coulter Partners secures Chief Executive Officer for ObsEva
Coulter Partners was delighted to partner with ObsEva SA (NASDAQ: OBSV / SIX: OBSN) to secure the appointment of Brian O’Callaghan as Chief Executive Officer and member of the company’s Executive Committee, effective 1 December 2020. He will succeed Dr Ernest Loumaye and be proposed for election on ObsEva’s Board of Directors at the next company AGM. ObsEva SA is a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health.
Please refer to ObsEva’s press release published on November 9th 2020: ObsEva appoints Brian O’Callaghan as CEO
Related
-
Events
DTx Europe: London 2024
12 December 2024 – 13 December 2024
-
Placement News
Top hires for VC & PE portfolio companies Q4-2021
25 January 2022
-
Placement News
Coulter Partners finds Chief Medical Officer for Memo Therapeutics AG
13 July 2021
-
Placement News
Coulter Partners places Board Director for ERYTECH Pharma
24 March 2020